In one study, PGRMC1 was found to induce erlotinib resistance, triggering crosstalk of the Wnt/β-catenin and NF-κB pathways in lung adenocarcinoma cells (Ma and Hottiger, 2016). This evidence concerns the gene NFKB1 and lung adenocarcinoma.